Alkermes Plc
ALKS
查看详细走势图
34.910USD
+1.360+4.05%
收盘 02/06, 16:00（美东）报价延迟15分钟
5.76B总市值
16.91市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.05%
5天
+3.01%
1月
+18.90%
6月
+31.49%
今年开始到现在
+24.77%
1年
+10.58%
查看详细走势图
TradingKey Alkermes Plc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Alkermes Plc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名1/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价43.81。中期看，股价处于平稳状态。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Alkermes Plc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Alkermes Plc亮点
亮点风险
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
业绩高增长
公司营业收入稳步增长，连续3年增长40.10%
估值高估
公司最新PE估值16.91，处于3年历史高位
机构减仓
最新机构持股175.23M股，环比减少0.01%
查克·罗伊斯持仓
明星投资者查克·罗伊斯持仓，最新持仓市值49.77K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.31
分析师目标
根据
17
位分析师
买入
评级
43.813
目标均价
+30.59%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Alkermes Plc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Alkermes Plc简介
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
公司代码ALKS
公司Alkermes Plc
CEOPops (Richard F)
网址https://www.alkermes.com/
相关品种
